Patterns of Methylphenidate Use and Assessment of Its Abuse among the General Population and Individuals with Drug Dependence

European Addiction Research

Volumn 22, Issue 3, 2016, Pages 119-126

  Frauger, Elisabeth ^a   Amaslidou, Despina ^b   Spadari, Michel ^b   Allaria Lapierre, Veronique ^c   Braunstein, David ^a   Sciortino, Vincent ^c   Thirion, Xavier ^d   Djezzar, Samira ^e   Micallef, Joelle ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b Service de Pharmacologie Clinique et Pharmacovigilance   (France)

^c Direction Regionale du Service Medical de la Region Provence Alpes Cote d'Azur et Corse   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Abuse of prescription drugs; Doctor shopping; Drug reimbursement database; Epidemiological surveillance; Methylphenidate; Patterns of use

Indexed keywords

BENZODIAZEPINE DERIVATIVE; METHYLPHENIDATE; OPIATE;

ABSCESS; ADULT; AGGRESSIVENESS; ANXIETY; ARTICLE; CLUSTER ANALYSIS; DEPRESSION; DISEASE ASSESSMENT; DRUG ABUSE; DRUG DEPENDENCE; DRUG USE; FATIGUE; FEMALE; HALLUCINATION; HEALTH CARE PERSONNEL; HEART DISEASE; HUMAN; HYPERACTIVITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NARCOLEPSY; PARANOIA; PATTERN RECOGNITION; PRIORITY JOURNAL; REIMBURSEMENT; TABLET; VIOLENCE; WEIGHT REDUCTION; ADOLESCENT; DIAGNOSIS; EPIDEMIOLOGICAL MONITORING; EPIDEMIOLOGY; FACTUAL DATABASE; FRANCE; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; YOUNG ADULT;

ADOLESCENT; ADULT; DATABASES, FACTUAL; EPIDEMIOLOGICAL MONITORING; FEMALE; FRANCE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; METHYLPHENIDATE; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84945116471     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000439273     Document Type: Article

References (42)

1. Kaye S, Darke S: The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction 2012; 107: 467-477.
2. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F: Trends in the prescribing of psy-chotropic medications to preschoolers. JAMA 2000; 283:1025-1030.
3. Swanson JM, Volkow ND: Psychopharmacol-ogy: concepts and opinions about the use of stimulant medications. J Child Psychol Psychiatry 2009; 50:180-193.
4. Berbatis CG, Sunderland VB, Bulsara M: Licit psychostimulant consumption in Australia, 1984-2000: international and jurisdictional comparison. Med J Aust 2002; 177:539-543.
5. Miller AR, Lalonde CE, McGrail KM, Armstrong RW: Prescription of methylphenidate to children and youth, 1990-1996. CMAJ 2001; 165:1489-1494.
6. Geirs DP, Pottegård A, Halldórsson M, Zoëga H: A nationwide study of attention-deficit/hyperactivity disorder drug use among adults in Iceland 2003-2012. Basic Clin Pharmacol Toxicol 2014; 115:417-422.
7. Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI: The use of medication against attention deficit/hyper activity disorder in Denmark: a drug use study from a patient perspective. Eur J Clin Pharmacol 2013; 69:589-598.
8. Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C: Abuse of methyl-phenidate in Germany: data from spontaneous reports of adverse drug reactions. Psychiatry Res 2014; 215:252-254.
9. Zetterqvist J, Asherson P, Halldner L, Lång-ström N, Larsson H: Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr Scand 2013; 128:70-77.
10. Trip AM, Visser ST, Kalverdijk LJ, de Jong-van den Berg LT: Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 2009; 67:466-468.
11. Treceño C, Martín Arias LH, Sáinz M, Salado I, García Ortega P, Velasco V, Jimeno N, Es-cudero A, Velasco A, Carvajal A: Trends in the consumption of attention deficit hyperac-tivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiol Drug Saf 2012; 21:435-441.
12. Frauger E, Pauly V, Natali F, Pradel V, Reggio P, Coudert H, et al: Patterns of methylpheni-date use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008. CNS Drugs 2011; 25:415-424.
13. Knellwolf AL, Deligne J, Chiarotti F, Auleley GR, Palmieri S, Boisgard CB, Panei P, Autret-Leca E: Prevalence and patterns of methyl-phenidate use in French children and adolescents. Eur J Clin Pharmacol 2008; 64:311-317.
14. Gerada C, Ashworth M: ABC of mental health. Addiction and dependence-I: illicit drugs. BMJ 1997; 315:297-300.
15. Lapeyre-Mestre M, Gony M, Carvajal A, Ma-cias D, Conforti A, D'Incau P, Heerdink R, Van der Stichele R, Bergman U: A European community pharmacy-based survey to investigate patterns of prescription fraud through identification of falsified prescriptions. Eur Addict Res 2014; 20:174-182.
16. Hernandez SH, Nelson LS: Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther 2010; 88:307-317.
17. Casati A, Sedefov R, et al: Misuse of medicines in the European union: a systematic review of the literature. Eur Addict Res 2012; 18:228-245.
18. McCabe SE, Teter CJ, Boyd CJ: The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse 2004; 39:1095-1116.
19. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, et al: Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008; 456:702-705.
20. Farquhar S, Fawcett P, Fountain J: Illicit intravenous use of methylphenidate (ritalin) tablets: a review of four cases. Aust Emerg Nurs J 2002; 5:25-29.
21. Dart RC: Monitoring risk: post marketing surveillance and signal detection. Drug Alcohol Depend 2009; 105(suppl 1):S26-S32.
22. Pauly V, Frauger E, Pradel V, Nordmann S, Pourcel L, Natali F, et al: Monitoring of ben-zodiazepine diversion using a multi-indicator approach. Int Clin Psychopharmacol 2011; 26: 268-277.
23. Mounteney J, Haugland S: Earlier warning: a multi-indicator approach to monitoring trends in the illicit use of medicines. Int J Drug Policy 2009; 20:161-169.
24. Nordmann S, Pradel V, Lapeyre-Mestre M, Frauger E, Pauly V, Thirion X, Mallaret M, Jouanjus E, Micallef J: Doctor shopping reveals geographical variations in opioid abuse. Pain Physician 2013; 16:89-100.
25. Pradel V, Thirion X, Ronfle E, Masut A, Mi-callef J, Bégaud B: Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiol Drug Saf 2004; 13:473-481.
26. Pradel V, Frauger E, Thirion X, Ronfle E, Lapierre V, Masut A, et al: Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf 2009; 18:36-43.
27. Frauger E, Moracchini C, Le Boisselier R, Braunstein D, Thirion X, Micallef J; French CEIPA-A Network: OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundam Clin Pharmacol 2013; 27:672-682.
28. Micallef J, Frauger E, Palmaro A, Boucherie Q, Lapeyre Mestre M: Example of an investigation of an 'emergent' phenomenon in addiction vigilance: the case of methylpheni-date. Therapie 2015; 70:191-202.
29. Zoëga H, Furu K, Halldórsson M, Thomsen PH, Sourander A, Martikainen JE: Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psy-chiatr Scand 2011; 123:360-367.
30. McDonald DC, Carlson KE: The ecology of prescription opioid abuse in the USA: geographic variation in patients' use of multiple prescribers ('doctor shopping'). Pharmaco-epidemiol Drug Saf 2014; 23:1258-1267.
31. Cepeda MS, Fife D, Berwaerts J, Yuan Y, Mas-trogiovanni G: Shopping behavior for ADHD drugs: results of a cohort study in a pharmacy database. Drugs R D 2014; 14:205-211.
32. Bjarnadottir GD, Rafnar BO, Sigurdsson E, Steingrimsson S, Bragadottir H, Haraldsson M, Magnusson A: Methylphenidate use among Icelandic i.v. substance abusers. Eur Psychiatry 2013; 28(suppl 1):P703.
33. Bruggisser M, Bodmer M, Liechti ME: Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Swiss Med Wkly 2011; 141:w13267.
34. Shlomi D, Shitrit D, Bendayan D, Sahar G, Shechtman Y, Kramer MR: Successful lung transplantation for talcosis secondary to intravenous abuse of oral drug. Int J Chron Obstruct Pulmon Dis 2008; 3:327-330.
35. Cook RC, Fradet G, English JC, Soos J, Müller NL, Connolly TP, et al: Recurrence of intravenous talc granulomatosis following single lung transplantation. Can Respir J 1998; 5: 511-514.
36. Ward S, Heyneman LE, Reittner P, Kazerooni EA, Godwin JD, Müller NL: Talcosis associated with IV abuse of oral medications: CT findings. AJR Am J Roentgenol 2000; 174: 789-793.
37. Stern EJ, Frank MS, Schmutz JF, Glenny RW, Schmidt RA, Godwin JD: Panlobular pulmonary emphysema caused by i.v. injection of methylphenidate (Ritalin): findings on chest radiographs and CT scans. AJR Am J Roent-genol 1994; 162:555-560.
38. Volkow ND, Swanson JM: Variables that affect the clinical use and abuse of methylphe-nidate in the treatment of ADHD. Am J Psychiatry 2003; 160:1909-1918.
39. Rigg KK, Ibañez GE: Motivations for non-medical prescription drug use: a mixed methods analysis. J Subst Abuse Treat 2010; 39: 236-247.
40. ANSM 2013-Données d'Utilisation et de Sécu-rité du Méthylphenidate en France, Juillet 2013. http://ansm.sante.fr/var/ansm-site/stor age/original/application/8dd1277a386715554 7b4dce58fc0db00.pdf (available December 23, 2014).
41. Karlstad Ø, Furu K, Skurtveit S, Selmer R: Prescribing of drugs for attention-deficit hy-peractivity disorder in opioid maintenance treatment patients in Norway. Eur Addict Res 2014; 20:59-65.
42. Pérez de los Cobos J, Siñol N, Pérez V, Trujols J: Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-def-icit/hyperactivity disorder and addiction. Br J Clin Pharmacol 2014; 77:337-356.